NVO 株価分析 — NOVO NORDISK A/S (Healthcare >> Drug Manufacturers - General)
NVO に関するよくある質問
NVOのPER(株価収益率)は?
NOVO NORDISK A/S(NVO)は現在PER 1.87倍で取引されています。
NVOのROE(自己資本利益率)は?
NOVO NORDISK A/SのROEは60.06%です。
NVOの配当利回りは?
NOVO NORDISK A/Sの配当利回りは3.49%です。
NVOの品質スコア(Quality Score)は?
当社のAIはNVOの総合財務品質を100点中54点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
NVOは今が買い時ですか?
当社AIのタイミングスコアは100点中89点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
NVOはどのセクターに属しますか?
NOVO NORDISK A/SはHealthcare >> Drug Manufacturers - Generalセクターに分類されます(NYSE市場)
NVO AI Analysis Summary
Our AI summary for NVO: NOVO NORDISK A/S (NYSE), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at a P/E of 1.87, ROE of 60.06%, a dividend yield of 3.49%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 47.08
Price
-4.53
(-8.78%)
Day Change
|
|
|---|
NVO, ファンダメンタルスコアはnot quite good ( ファンダメンタル = 54) but テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEの伸びが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are ok , financial health is not quite good , and ability to make profit is good , ...
| Deepscope 分析 |
|
69% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 1.96 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
59
GOOD
|
| Magic Formula Rank by ROE |
59
GOOD
|
| Magic Formula Rank by ROIC |
110
|
| Price | 47.08 |
| PBV / Sector |
1.12 / 2.68
GREAT
|
| Earning Per Share | 25.16 |
| PE / Sector |
1.87 / 27.65
GREAT
|
| PEG or PE/Growth / Sector |
0.07 / 0.28
GREAT
|
| Average 1M Daily Value |
445.54 M
GREAT
|
| Average 1W Daily Value |
589.29 M
|
| Timing Factors |
|
57% |
| Financial Health |
|
54% |
| ポイントになる統計 |
|
77% |
| 配当 |
|
62% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:15 |
| Symbol | NVO |
| Name | NOVO NORDISK A/S |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NYSE |
| Listed Shares | 3,347.02 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 228,214.05 / 256,404.20 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Novo Alle 1, Bagsvaerd, Denmark, 2880
Phone: 45 44 44 88 88
Website: https://www.novonordisk.com
Employees: 67,900
Description: Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
Google